Article
type: Class

Document
type: Class

individual
rights: termsOfUse
date: 2026-08-25T04:54:01
publisher: Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
type: Document
label: RDF description of Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis - http://irises.unipv.it/resource/item/90718

Inglese
type: Language

Information Content Entity
type: Class

Academic Article
type: Class

Continuant
type: Class

Entity
type: Class

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
type: Generically Dependent Continuant
type: Article
type: Thing
language: Inglese
type: Document
type: Information Content Entity
type: Continuant
type: Academic Article
type: Entity
most specific type: Academic Article

Generically Dependent Continuant
type: Class